Non ST elevation myocardial infarction pathophysiology

Jump to navigation Jump to search


Resident
Survival
Guide

Acute Coronary Syndrome Main Page

Unstable angina / NSTEMI Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Unstable Angina
Non-ST Elevation Myocardial Infarction

Differentiating Unstable Angina/Non-ST Elevation Myocardial Infarction from other Disorders

Epidemiology and Demographics

Risk Stratification

Natural History, Complications and Prognosis

Special Groups

Women
Heart Failure and Cardiogenic Shock
Perioperative NSTE-ACS Related to Noncardiac Surgery
Stress (Takotsubo) Cardiomyopathy
Diabetes Mellitus
Post CABG Patients
Older Adults
Chronic Kidney Disease
Angiographically Normal Coronary Arteries
Variant (Prinzmetal's) Angina
Substance Abuse
Cardiovascular "Syndrome X"

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Blood Studies
Biomarkers

Electrocardiogram

Chest X Ray

Echocardiography

Coronary Angiography

Treatment

Primary Prevention

Immediate Management

Anti-Ischemic and Analgesic Therapy

Cholesterol Management

Antitplatelet Therapy

Antiplatelet therapy recommendations
Aspirin
Thienopyridines
Glycoprotein IIb/IIIa Inhibitor

Anticoagulant Therapy

Additional Management Considerations for Antiplatelet and Anticoagulant Therapy

Risk Stratification Before Discharge for Patients With an Ischemia-Guided Strategy of NSTE-ACS

Mechanical Reperfusion

Initial Conservative Versus Initial Invasive Strategies
PCI
CABG

Complications of Bleeding and Transfusion

Discharge Care

Medical Regimen
Post-Discharge Follow-Up
Cardiac Rehabilitation

Long-Term Medical Therapy and Secondary Prevention

ICD implantation within 40 days of myocardial infarction

ICD within 90 days of revascularization

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Non ST elevation myocardial infarction pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non ST elevation myocardial infarction pathophysiology

CDC onNon ST elevation myocardial infarction pathophysiology

Non ST elevation myocardial infarction pathophysiology in the news

Blogs on Non ST elevation myocardial infarction pathophysiology

to Hospitals Treating Non ST elevation myocardial infarction pathophysiology

Risk calculators and risk factors for Non ST elevation myocardial infarction pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.

Overview

Unstable angina and NSTEMI are at different ends of the spectrum of the same disease. While there is no way to determine which patients presenting with unstable angina will ultimately progress to NSTEMI, the distinction between the two entities is clear. Often, for patients presenting prior to the four hour window before cardiac biomarkers are positive (namely CK-MB), the EKG in context of the patient's chest pain will be marker for whether patient has STEMI versus UA/NSTEMI and needs to urgently undergo percutaneous revascularization.

Pathophysiology

Complete List of (Known) Underlying Mechanisms of NSTEMI

Plaque Rupture, Thrombus Formation, and Embolization Underly the Pathophysiology of NSTEMI

  • This video shows plaque rupture or disruption of the atherosclerotic plaque in the mid left anterior descending artery (LAD) .
  • As is often the case, the plaque has torn at its edge, a location where the fibrous cap covering the atherosclerotic plaque is the thinnest.
  • Clot has formed and it is embolizing downstream.
  • The most common preceding pathophysiologic event in NSTEMI is the disruption of an atherosclerotic plaque in an epicardial coronary artery, as shown here.
  • Exposure of the atherosclerotic plaque contents to the blood stream leads to activation of the clotting cascade, local thrombus formation, and incomplete occlusion of the epicardial artery in NSTEMI.
  • This artery is open, in NSTEMI unlike STEMI where the artery is closed.
  • The downstream microvasculature is occluded by the clot that has embolized, and this accounts for the troponin elevation in this patient.

Original Hypothesis

  • As opposed to the original hypothesis that acute coronary syndrome (ACS) is caused by gradual progression of coronary atherosclerosis to the point of a severe, fixed lesion, it has become clear that, in fact, ACS is usually caused by atherosclerotic plaque rupture at a site that previously had only mild to moderate stenosis.[1]
  • This plaque rupture exposes ligands (including collagen) for platelet adhesion which causes platelet aggregation and subsequent platelet activation.[2]
  • Platelets are activated by thrombin (found in blood clots), adenosine diphosphate (found in platelet granules), serotonin (also found in platelet granules), and thromboxane-A2.[2]
  • Upon activation, the glycoprotein IIb/IIIa receptor, that in a non-active state is found in the cytosol, is exteriorized and modified which enables additional platelet aggregation and cross-linking.[1]
  • The prothrombinase complex then binds to the activated platelet and starts the coagulation cascade.[1]
  • This entire process results in a thrombus which coalesces over the ruptured plaque.

Below is the animation showing clot formation which breaks off to embolize artery downstream: {{#ev:youtube|T_t-0cAP1C4}}

Other Mechanisms

Although less common, ACS may also occur by other mechanisms. These include:

Genetics

  • To date, there does not appear to be any single genetic marker predictive of acute coronary syndrome (ACS).[3]
  • In a recent validation study of genetic variants associated with (which includes STEMI, NSTEMI, and UA) none of the 85 genetic variants tested were shown to be correlated with ACS. The study chose the polymorphic genetic variants based on statistically significant findings of prior studies.[4]
  • Nonetheless, although no individual marker is likely to be predictive, in the future it is possible that a panel of markers may be used to assess risk.[3][5]

Microscopic Pathology

Plaque rupture in a coronary artery at arrows yielding obstructive thrombus in red.


References

  1. 1.0 1.1 1.2 Martinez-Rumayor A, Januzzi JL (2006). "Non-ST segment elevation acute coronary syndromes: A comprehensive review". Southern Medical Journal. 99 (10): 1103–10. PMID 17100031. Retrieved 2011-04-11. Unknown parameter |month= ignored (help)
  2. 2.0 2.1 Patrono C, Renda G (1997). "Platelet activation and inhibition in unstable coronary syndromes". The American Journal of Cardiology. 80 (5A): 17E–20E. PMID 9296464. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  3. 3.0 3.1 Anwaruddin S, Askari AT, Topol EJ (2007). "Redefining risk in acute coronary syndromes using molecular medicine". Journal of the American College of Cardiology. 49 (3): 279–89. doi:10.1016/j.jacc.2006.08.051. PMID 17239708. Retrieved 2011-04-11. Unknown parameter |month= ignored (help)
  4. Morgan TM, Krumholz HM, Lifton RP, Spertus JA (2007). "Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study". JAMA : the Journal of the American Medical Association. 297 (14): 1551–61. doi:10.1001/jama.297.14.1551. PMID 17426274. Retrieved 2011-04-11. Unknown parameter |month= ignored (help)
  5. Wilcken DE (2003). "Overview of inherited metabolic disorders causing cardiovascular disease" (PDF). Journal of Inherited Metabolic Disease. 26 (2–3): 245–57. PMID 12889664. Retrieved 2011-04-11.

Template:WH Template:WS